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Introduction
Fibromyalgia (FM) is a common disorder that affects approximately 2% to 5% of the general population in V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com the United States, Canada, and Europe [1] [2] [3] [4] and is characterized by chronic widespread pain, tenderness, and fatigue [5] . While different pharmacological therapies are available for the treatment of FM [6, 7] , they do not necessarily provide a clinically meaningful improvement in FM-related pain for every patient, perhaps due to their different mechanisms of action [6, [8] [9] [10] [11] . Identifying treatment responders, that is, those patients who benefit from a given treatment, can help refine treatment options and maximize patient outcomes while minimizing exposure to drugs for those patients who are less likely to respond. Examining patient characteristics and their effect on the response to treatment is one method of identifying patients who may be treatment responders vs those who may not be.
The efficacy and safety of pregabalin in FM has been demonstrated in multiple placebo-controlled clinical studies [12] [13] [14] [15] [16] [17] , and it is approved for the treatment of FM in several countries including the United States [18] . Post hoc analyses of these studies have examined the effect of patient characteristics on the treatment response to pregabalin vs placebo [19] [20] [21] [22] [23] . However, patients with depression or who were taking antidepressants were actively excluded from these studies [12, 14, 15, 17] . The effect of patient characteristics on treatment response has therefore not been determined in patients with FM taking antidepressant medication for comorbid depression, who may comprise 25% to 60% of the FM population [1, 24] .
The results of a phase IIIb clinical study of pregabalin efficacy and safety in FM patients taking either a single selective serotonin reuptake inhibitor (SSRI) or a serotonin/norepinephrine reuptake inhibitor (SNRI) for treating comorbid depression were recently reported [25] . Pregabalin significantly (P < 0.001) improved the mean pain score primary efficacy end point (based on an 11-point numeric rating scale [NRS]) compared with placebo (treatment difference ¼ -0.6, 95% confidence interval [CI] ¼ -0.9 to -0.3) and had a safety profile consistent with previous studies [25] . Pregabalin also significantly improved mean pain scores compared with placebo in patients taking different antidepressants (SSRI: treatment difference ¼ -0.5, 95% CI ¼ -0.9 to -0.1, P ¼ 0.021; SNRI: treatment difference ¼ -0.8, 95% CI ¼ -1.2 to -0.3, P ¼ 0.001). Moreover, significantly more patients were 30% (45.3% vs 27.7%, P < 0.001) and 50% (26.0% vs 15.8%, P ¼ 0.021) pain responders with pregabalin compared with placebo at the study end point. Nonetheless, not every patient had a clinically meaningful improvement in pain severity with pregabalin treatment. This clinical study provides an opportunity to examine if patient characteristics had an effect on the response to pregabalin treatment in patients with FM taking antidepressant medication for comorbid depression, a population that has not been extensively studied in a controlled clinical environment. Here, we evaluate which patient baseline characteristics affect the pain response to pregabalin compared with placebo in this patient population.
Methods

Study Design
Details of the study design have been described previously [25] . Briefly, patients from 38 centers in the United States, Italy, Spain, and Canada were enrolled in a randomized, placebo-controlled, two-way crossover, phase IIIb study of pregabalin efficacy and safety. The study protocol and informed consent documents were reviewed and approved by an institutional review board or independent ethics committee at each participating site, and written informed consent was obtained from each patient prior to inclusion in the study. The study was conducted in accordance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines for Biomedical Research Involving Human Subjects, and the International Conference on Harmonisation Good Clinical Practice Guidelines, and it was registered online at ClinicalTrials.gov (NCT01432236).
Participants were age 18 years or older with an FM diagnosis based on the 1990 American College of Rheumatology criteria [5] ; had a mean pain score of 4 or higher on an 11-point NRS (0 ¼ no pain, 10 ¼ worst possible pain) at randomization and screening; had a confirmed diagnosis of major depressive disorder (MDD), dysthymia, or depression not otherwise specified (NOS); and were treated with a single SSRI or SNRI for three or more months with no change in medication type, and at a stable dose for two or more months prior to randomization. Patients were randomized 1:1 to receive pregabalin followed by placebo or placebo followed by pregabalin, with double-blind treatment occurring for two six-week treatment periods separated by a two-week taper/washout period to prevent any potential carryover of treatment effects. Pregabalin dosing in a twice-daily allocation was started at 150 mg/day, optimized to 300 or 450 mg/day during the first three weeks of each treatment period, and then maintained at this dose for the remaining three weeks of treatment. Stable antidepressant medication was continued for the duration of the study, although adjustments for safety reasons were permitted. The primary efficacy end point was the mean pain score for pregabalin vs placebo calculated as the mean of the last seven daily pain scores. Data from the two treatment periods were combined to produce a single efficacy end point.
Patient Baseline Characteristics
This post hoc analysis determined the effect of patient baseline characteristics on the mean pain score primary efficacy end point. Patients were grouped according to each characteristic, and the effect on the mean pain score at study end point for pregabalin vs placebo was determined.
The baseline characteristics assessed were based on patient demographics, patient medical history, and baseline scores for efficacy measures of interest used in the clinical study. Patients were assessed by their age (in years) at the time of the study. Body mass index (BMI, in kg/m 2 ) was calculated from each patient's weight and height. The timing of FM and depression diagnoses was ascertained, and patients were assessed according to whether the FM diagnosis was before or at the same time as the depression diagnosis, or whether the depression diagnosis was before the FM diagnosis. FM duration since diagnosis (in years) was determined. The number of FM medications used before the start of the study was calculated for each patient based on patient's recall and/or the investigator's direct knowledge from medical records. Patients were then stratified according to whether they had previously used zero, one or two, or three or more FM medications at any time. Depression duration since diagnosis (in years) was determined. Median depression duration at baseline (10.9 years) was used to group patients by shorter-(<10 years) or longer-term (10 years) depression. Patients were also assessed depending on their depression diagnosis (MDD, dysthymia, or depression NOS). Mean antidepressant dose for the SSRI/SNRI used in the study was calculated as the mean dose in the first week after randomization. Patients were categorized as taking a low or high dose for each antidepressant based on the mean dose used during the study and current product labeling. Table 1 lists the antidepressants that were used during the study and the thresholds used to define low and high doses for each antidepressant. Patients were then grouped across all antidepressants into those taking a low dose or those taking a high dose. Patients were also analyzed depending on the presence of common FM-associated comorbid conditions in addition to depression as reported by each study site. The classification of comorbid conditions was based on terms in the Medical Dictionary for Regulatory Activities coding dictionary (version 16.0). All comorbid conditions were captured, and those that provided a large enough sample size to be analyzed were headache (headache, migraine, migraine with aura, sinus headache, and tension headache), insomnia (insomnia and sleep disorder), osteoarthritis (arthritis, osteoarthritis, and spinal osteoarthritis), gastroesophageal reflux disease (GERD; dyspepsia and GERD), and irritable bowel syndrome (IBS). Each comorbid condition was analyzed separately. Patients were evaluated depending on whether they had or had not used opioid medications for the treatment of FM at any time before the start of the study, based on patient's recall and/or the investigator's direct knowledge from medical records. The opioid medications (or their salts) with observed use prior to the start of the study and that were assessed were dextropropoxyphene hydrochloride, fentanyl, hydrocodone with or without acetaminophen or ibuprofen, morphine (morphine sulfate), oxycodone with or without acetaminophen, tapentadol, and tramadol (tramadol hydrochloride) with or without acetaminophen. Mean pain score was used to stratify patients by pain severity [26] : moderate, 4 to <7; and severe, 7 to 10. Patients with mild pain, that is, a mean pain score from 0 to <4, were ineligible for inclusion in the study. The Fibromyalgia Impact Questionnaire (FIQ) total score from 0 to 100 [27] was used to group patients by FM severity [27, 28] : mild, 0 to <39; moderate, 39 to <59; and severe, 59 to 100. The Hospital Anxiety and Depression Scale-Anxiety (HADS-A) and -Depression (HADS-D) scores from 0 to 21 [29] were used to analyze patients by their anxiety and depression severity, respectively. The median scores for HADS-A and HADS-D at baseline were 8.0 for both measures. Patients with scores lower than 8 were categorized as having less severe anxiety or depression, while those with scores of 8 or higher were categorized as having more severe anxiety or depression. Sleep quality, recorded as part of a daily sleep diary, was based on an 11-point NRS (0 ¼ worst sleep quality and 10 ¼ best sleep quality) [25] . Sleep quality score was used to evaluate patients by their sleep disruption severity: mild, 7 to 10; moderate, 4 to <7; and severe, 0 to <4. Latency-to-sleep onset (LSO), also recorded as part of a daily sleep diary, was used as a surrogate measure for the presence of comorbid insomnia. Based on insomnia criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) [30] , patients with an LSO of 30 minutes or longer were taken as representative of those with comorbid insomnia.
Statistical Analysis
The primary efficacy end point was analyzed using a linear mixed effects model including sequence, period, and treatment as fixed factors, and subject within sequence and within subject error as random factors. Imputation of missing data was based on the last observation carried forward or mixed model repeated measures. Baseline characteristics were included in the model as variables. Age, BMI, FM duration since diagnosis, and depression duration since diagnosis were analyzed as continuous variables. To further explore the effect of depression duration on pain responses, we also analyzed depression duration since diagnosis as a categorical variable (duration < 10 years or 10 years, based on median depression duration across the sample population of 10.9 years). First diagnosis, number of previous FM medications, depression diagnosis, antidepressant dose, presence of individual comorbid conditions, opioid use, pain severity, FM severity, anxiety severity, depression severity, sleep disruption severity, and LSO were also analyzed as categorical variables. Statistical significance was set at a P value of less than 0.05.
Results
Study Population
A total of 318 patients were screened, and 197 were randomized to treatment. Of these, four patients were randomized in error but did not receive treatment. The study population, therefore, comprised the 193 patients who received at least one dose of treatment. Across the two study periods, 181 patients received at least one dose of pregabalin and 177 at least one dose of placebo. The characteristics of the study population at baseline are shown in Table 2 . Baseline scores for the efficacy measures of interest are shown in Table 3 . Some of these results have been described previously [25] .
Treatment responses could not be determined for some baseline characteristics because of the small sample sizes: only 13 patients (6.7%) took no FM medications prior to the start of the study; eight patients (4.2%) had dysthymia; two patients (1.0%) had mild FM (FIQ total score from 0 to <39); and 16 patients (8.3%) had mild sleep disruption (sleep quality score from 7 to 10).
Effect of Baseline Characteristics on Treatment Response
Pregabalin significantly improved mean pain score vs placebo for the majority of baseline characteristics examined (Tables 4-6 ). A significant treatment difference between pregabalin and placebo was observed when depression duration since diagnosis was analyzed as a continuous variable (Table 4) . To further assess the effect of depression duration on treatment response, we analyzed depression duration since diagnosis as a categorical variable based on median duration since diagnosis (10.9 years). Patients were categorized as having shorter-term depression (time since diagnosis < 10 years) or longer-term depression (time since diagnosis 10 years). When analyzed in this way, a significant treatment difference between pregabalin and placebo was observed in patients with shorter-term depression, but no difference was seen in those with longer-term depression (Table 5) . Moreover, pregabalin did not significantly improve mean pain score vs placebo in patients diagnosed with depression before FM (Table 5) , in those taking a high dose of antidepressant (Table 5) , or in those with more severe depression (HADS-D score 8) (Table 6 ). Pregabalin also did not significantly improve mean pain score vs placebo in patients with comorbid insomnia, GERD, or IBS (Table  5) , or in those with severe FM (FIQ total score from 59 to 100) ( Table 6 ). We attempted to further examine the lack of effect of pregabalin in patients with comorbid ScaleDepression. *Patients were classified as having moderate or severe pain based on mean pain score at baseline as assessed on an 11-point numeric rating scale (moderate, 4 to < 7; severe, 7 to 10). Note that patients with a mean pain score of < 4 at baseline, that is, mild pain, were excluded from the study. † Patients were classified as having mild, moderate, or severe FM based on FIQ total score at baseline (mild, 0 to < 39; moderate, 39 to < 59; severe, 59 to 100). ‡ One patient was missing an FIQ total score at baseline. § Patients were classified as having mild, moderate, or severe sleep disruption based on sleep quality score at baseline as assessed on an 11-point numeric rating scale (mild, 7 to 10; moderate, 4 to < 7; severe, 0 to < 4). ¶ One patient was missing a sleep quality score at baseline. Note that data were rounded to 1 decimal point for clarity, except for P values. BMI ¼ body mass index; CI ¼ confidence interval; FM ¼ fibromyalgia. insomnia, GERD, or IBS by examining those patients who were taking concomitant medications for these conditions. However, there were too few patients taking medications for insomnia, GERD, or IBS to provide meaningful analysis (data not shown). For insomnia, we analyzed LSO as a surrogate measure for the presence of comorbid insomnia, with a cutoff based on DSM-5 criteria [30] . In patients with an LSO of 30 minutes or longer (N ¼ 131), pregabalin significantly improved mean pain score vs placebo (Table 6 ).
Discussion
In a recent phase IIIb study, pregabalin demonstrated efficacy for FM in patients with comorbid depression receiving an SSRI or SNRI for the treatment of their depression [25] . The results of this post hoc analysis of that study population show that pregabalin significantly improved pain severity when compared with placebo irrespective of the majority of baseline characteristics examined. However, there were some baseline characteristics in which improvements in pain relief with pregabalin compared with placebo were not statistically significant. These included comorbid insomnia, GERD, or IBS; severe FM (FIQ total score from 59 to 100); a diagnosis of depression before FM; taking a high dose of antidepressant; longer-term depression (duration 10 years); and severe depression (HADS-D score 8).
FM patients with more severe FM, or those with longerterm or more severe depression, may represent patients who are hard to treat with pregabalin as well as other therapies. Several studies have reported that FM-related symptom burden increases as FM severity worsens, reflected in greater health care resource utilization, reduced productivity, and increased economic costs [31] [32] [33] [34] [35] [36] . Patients with severe FM took more FM-related medications than those with less severe FM [33] , and greater FM severity was associated with more patients using more FM medications [31, 36] . Moreover, the perceived effectiveness of prescription FM medications appears to decrease as FM severity worsens, and those with severe FM are less satisfied with these medications than those with less severe FM [32, 35] . Severity of depression in FM patients is associated with more physical symptoms and poorer functioning, compared with patients with chronic widespread pain but no diagnosis of FM [37] . It has also been reported that medical FM symptoms and functional disability are positively linked Note that data were rounded to 1 decimal point for clarity, except for P values. CI ¼ confidence interval; FM ¼ fibromyalgia; HADS-A ¼ Hospital Anxiety and Depression Scale-Anxiety; HADS-D ¼ Hospital Anxiety and Depression Scale-Depression; LSO ¼ latency to sleep onset. *Based on mean pain score at baseline on an 11-point numeric rating scale (moderate, 4 to <7; severe, 7 to 10). † Based on FIQ total score at baseline (moderate, 39 to <59; severe, 59 to 100). ‡ Based on sleep quality score at baseline on an 11-point numeric rating scale (moderate, 4 to <7; severe, 0 to <4).
to both current and past depression diagnosis [38] . Depressive symptoms are also associated with higher pain perception [39] and worse quality of life [39] [40] [41] .
Patients with FM and comorbid depression have high health care costs that are greater than the sum of each condition alone [42] . Although pregabalin did not improve pain severity in patients with severe FM or more long-term or severe depression, it may be of value as part of a multimodal and multidisciplinary treatment regimen for these difficult-to-treat patients.
A series of post hoc analyses of randomized, doubleblind, placebo-controlled studies of pregabalin efficacy have examined the effect of baseline characteristics on treatment responses to pregabalin in FM patients who did not have depression and who were not taking an antidepressant. An analysis of a single study reported improvements in pain severity with pregabalin vs placebo that were independent of baseline anxiety or depression scores [20] . These findings were extended in a pooled analysis of three studies, which confirmed that baseline levels of anxiety or depression did not affect improvements in pain [21] . In a pooled analysis of two studies, FM severity predicted the time to pain improvement with pregabalin at doses of 300 to 600 mg/day [23] . Patients with higher FIQ total score required more time for their pain to improve compared with patients with a lower score. In a pooled analysis of four studies, pregabalin at approved doses (300 and 450 mg/day) significantly improved pain severity when compared with placebo irrespective of baseline mean pain score or age [19] . Pregabalin was also significantly better than placebo in patients with more sleep disruption at baseline, but not in patients with better sleep [19] . Finally, in a different pooled analysis of the same four studies, the effect of patient comorbid conditions on pregabalin efficacy was evaluated [22] . Doses of pregabalin (300 or 450 mg/day) were analyzed separately. Irrespective of dose, pregabalin significantly improved pain severity vs placebo irrespective of the presence of headache, immune disorders or allergies, GERD, insomnia, depression, neurological conditions, and asthma, but not anxiety or restless leg syndrome [22] . Pregabalin at a dose of 450 mg/day, but not 300 mg/day, was also significantly better than placebo in patients with IBS. This contrasts with the current study, where pregabalin did not significantly improve pain severity in patients with comorbid insomnia, GERD, or IBS, although there was a clear trend toward improvement with pregabalin in patients with insomnia and IBS. The reasons for the discrepancies between the studies are not clear. Insomnia is a diagnostic criterion for MDD [30] , perhaps indicating that patients in the current study who have comorbid depression and insomnia are particularly hard to treat. It should be noted, though, that in the current study pregabalin did significantly improve pain compared with placebo in patients with severe sleep disruption and in patients with LSOs of 30 minutes or longer, a surrogate measure for the presence of insomnia. Moreover, the sample sizes of patients with comorbid GERD (N ¼ 51) or IBS (N ¼ 40) were relatively small, particularly compared with previous analysis [22] , although they were comparable in size to some other variables analyzed here. The results from the current study also support recent findings from pooled analyses on the benefit of pregabalin in patients irrespective of the presence of comorbid osteoarthritis [43] or prior opioid use [44] . In short, these results extend previous findings on the effect of baseline characteristics on the efficacy of pregabalin, albeit in patients who were taking an antidepressant for comorbid depression, an FM population that was actively excluded from previous pregabalin trials.
This study had several possible limitations. Participants had to meet the criteria for inclusion in the original clinical study, so findings may not be generalizable to the wider FM population. This was a post hoc analysis, and the original study was not powered to test the effect of any of the variables on the primary efficacy end point. Moreover, analyzing characteristics as categorical variables reduced statistical power due to reduced sample size, which may have contributed to nonsignificance in some cases. The presence of comorbidities was based on self-reporting by the patients rather than clinical diagnosis. Durations of FM and depression were based either on documentation in patients' medical record or patient self-reporting, and were therefore also at risk of recall bias. An additional challenge in the diagnoses of both FM and depression is the subjectivity of symptoms. Only a limited number of antidepressants was permitted. Treatment responses in patients who took no prior FM medication, and those who had dysthymia, FM of mild severity, or sleep disruption of mild severity, could not be determined because there were too few patients to analyze. Finally, although pain is the cardinal symptom of FM [5] , other symptoms that are important in FM, for example, sleep disruption, anxiety/depression, fatigue, impaired quality of life, etc., were not evaluated.
Conclusions
Pregabalin significantly improved mean pain scores compared with placebo irrespective of a wide variety of baseline characteristics in patients who were taking a single SSRI or SNRI for comorbid depression. In agreement with previous studies, these findings support the view that pregabalin would be a suitable treatment option for reducing pain severity in a wide population of FM patients. 
